LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Yopp, A., Kudo, M., Chen, M., Cheng, A-L., Kaseb, A.O., Lee, H.C., Qin, S., Cha, E., Hack, S.P., Lian, Q., Spahn, J., Wu, C., Chow, P.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
He, A.R.R., Numata, K., Lee, K-H., Hsu, C-H., Lee, J., Morimoto, M., Verret, W., Hack, S.P., Spahn, J., Liu, B., Ryoo, B-Y.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
LBA5_PRPHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB + COBIMETINIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION–POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA (NCT01689519)
McArthur, G.A., Ascierto, P.A., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandalà, M., Demidov, L.V., Stroyakovsky, D., Thomas, L., De La Cruz Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Chang, I., Hack, S.P., Dréno, B.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)
McArthur, G.A., Ascierto, P.A., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandalà, M., Demidov, L.V., Stroyakovsky, D., Thomas, L., De La Cruz Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Chang, I., Hack, S.P., Dréno, B.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Évaluation de la qualité de vie (QdV) chez des patients atteints d’un mélanome métastatique traités par vemurafenib (V) et cobimetinib (C)
Dréno, B., Bartley, K., Ascierto, P.A., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Dutriaux, C., Garbe, C., Chang, I., Hack, S.P., Larkin, J., McArthur, G.A., Ribas, A.
Published in Annales de dermatologie et de vénéréologie (01.12.2015)
Published in Annales de dermatologie et de vénéréologie (01.12.2015)
Get full text
Journal Article
Mise à jour de la survie sans progression (PFS) et analyse de corrélation des biomarqueurs de coBRIM : Étude de phase 3 de cobimétinib (cobi) associé à vémurafénib (vem) dans le mélanome avancé avec mutation BRAF
Thomas, L., Larkin, J., Dutriaux, C., Yan, Y., McArthur, G., Ascierto, P., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stoyakovskiy, D., de la Cruiz-Merino, L., Atkinson, V., Garbe, C., Wongchenko, M., Rooney, I., Chang, I., Hack, S.P., Ribas, A., Dréno, B.
Published in Annales de dermatologie et de vénéréologie (01.12.2015)
Published in Annales de dermatologie et de vénéréologie (01.12.2015)
Get full text
Journal Article